Novartis Seeks To Stop Hospira From Selling Zometa Generic

Law360, New York (August 6, 2013, 4:52 PM EDT) -- Novartis Pharmaceuticals Corp. launched a lawsuit against Hospira Inc. in New Jersey federal court Friday seeking to block the company’s attempt to manufacture and sell generic versions of Novartis’ cancer therapy drug Zometa prior to expiration of two of its patents. 

The New Jersey-based pharmaceutical company alleges that Hospira requested approval from the U.S. Food and Drug Administration to manufacture and sell generic versions of Novartis’ Zometa product before the expiration of U.S. Patent Numbers 7,932,241 and 8,324,189.

This is not the first time the company...
To view the full article, register now.